课题基金 / 基金详情

Targeting triple-negative breast cancer stem cells and simultaneously boosting anti-tumor immunity.

Targeting triple-negative breast cancer stem cells and simultaneously boosting anti-tumor immunity.
靶向三阴性乳腺癌干细胞，同时增强抗肿瘤免疫力。
批准号：
476301
负责人：
Mediratta Karan
金额：
$7.65万
依托单位：
University of Ottawa
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-11-01 至 2025-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=476301&lang=en
关键词：
Breast Cancer Cancer Immunotherapy Cancer Stem Cells Cd73 Adenosine Signalling Pathway Drug Repurposing Exosomes For Drug Delivery Immune Checkpoint Inhibition In Vivo Tumor Modeling Patient-Derived Xenograft (Pdx) Wnt, Yap, Pi3k, Akt Signalling

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that accounts for 10-15% of breast cancer cases and the majority of breast cancer-related deaths. Despite recent research progresses, chemotherapy remains the main option fo
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金